Abstract
Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.
Keywords: Adalimumab, psoriasis, biological agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Adalimumab
Volume: 6 Issue: 3
Author(s): Meltem Uslu
Affiliation:
Keywords: Adalimumab, psoriasis, biological agents
Abstract: Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.
Export Options
About this article
Cite this article as:
Meltem Uslu , Adalimumab, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368210
DOI https://dx.doi.org/10.2174/187152307781368210 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets Multi-Constituent Cardiovascular Pills (MCCP) - Challenges and Promises of Population-Based Prophylactic Drug Therapy for Prevention of Heart Attack
Current Pharmaceutical Design Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets The Clinical Genetics of Psoriasis
Current Genomics Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lectin Techniques for Glycoproteomics
Current Proteomics Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Perspectives of Engineered Marine Derived Polymers for Biomedical Nanoparticles
Current Pharmaceutical Design Randomized, Placebo Controlled Study of the Effects of Etoricoxib on Markers of Inflammation, Pain and Muscle Force After Eccentric Exercise
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Mast Cells as Critical Effectors of Host Immune Defense against Gram-negative Bacteria
Current Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Functional Components from Nature-Derived Drugs for the Treatment of Rheumatoid Arthritis
Current Drug Targets Identification of a Novel Glutathione Conjugate of Diclofenac by LTQOrbitrap
Drug Metabolism Letters Inflammation: A Link Between Hypertension and Atherosclerosis
Current Hypertension Reviews Application of ImageJ Software for the Quantification of Hand Joint Space Narrowing in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience